Hospital
Adena Fayette Medical Center
Adena Fayette Medical Center was paid $14.39M by Medicaid between Jan 2018 and Dec 2024, across 244 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoADENA FAYETTE MEDICAL CENTER
WASHINGTON COURT HOUSE, OH 43160
WASHINGTON COURT HOUSE, OH 43160
33aNPI1508978677assigned 08/31/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$14.39M
24GClaims428,523
24DCodes billed244
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,609 | $994K | |
| 2019 | 54,898 | $1.17M | |
| 2020 | 36,695 | $1.40M | |
| 2021 | 35,991 | $1.35M | |
| 2022 | 34,967 | $1.42M | |
| 2023 | 123,627 | $3.88M | |
| 2024incomplete | 100,736 | $4.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 17,257 | 15,409 | $2.11M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 12,665 | 10,587 | $1.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.7% | 11,054 | 8,099 | $1.25M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.1% | 10,266 | 7,709 | $1.02M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.6% | 3,373 | 2,266 | $657K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.3% | 8,072 | 2,269 | $623K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.9% | 7,577 | 6,249 | $565K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.8% | 5,879 | 1,874 | $549K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 3,841 | 3,356 | $539K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.6% | 4,946 | 3,976 | $516K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 1,780 | 1,289 | $392K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 1,294 | 949 | $390K |
232 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.6% | 5,459 | $371K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.3% | 1,208 | $328K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 2,214 | $272K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.8% | 1,838 | $264K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.7% | 2,763 | $240K |
| 80053 | Comprehensive metabolic panel | 1.6% | 25,664 | $231K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.4% | 2,578 | $205K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.4% | 866 | $204K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 595 | $180K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,573 | $126K |
| G0378 | Hospital observation service, per hour | <1% | 3,975 | $120K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,204 | $107K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,570 | $85K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,890 | $81K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,898 | $67K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 766 | $59K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,490 | $59K |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,984 | $58K |
| 80061 | Lipid panel | <1% | 3,260 | $44K |
| 97162 | <1% | 878 | $44K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,016 | $43K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,317 | $42K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,442 | $41K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 912 | $38K |
| 87081 | <1% | 1,387 | $31K | |
| 82607 | <1% | 1,529 | $30K | |
| 20611 | <1% | 169 | $30K | |
| 84484 | <1% | 11,125 | $29K | |
| 87088 | <1% | 3,123 | $29K | |
| 20610 | <1% | 224 | $29K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 507 | $21K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 138 | $18K |
| 95886 | <1% | 64 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 919 | $16K |
| 71250 | <1% | 173 | $15K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 138 | $15K |
| 83605 | <1% | 4,389 | $15K | |
| 83655 | <1% | 395 | $13K | |
| 96367 | <1% | 213 | $13K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 203 | $13K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 81 | $12K |
| 73630 | <1% | 806 | $12K | |
| 83735 | <1% | 4,715 | $12K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 47 | $12K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,479 | $12K |
| 82728 | <1% | 749 | $12K | |
| 85027 | <1% | 2,190 | $12K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 53 | $11K |
| 73562 | <1% | 599 | $11K | |
| 72100 | <1% | 238 | $11K | |
| 82570 | <1% | 898 | $11K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 128 | $10K |
| 85610 | <1% | 4,568 | $10K | |
| 84439 | <1% | 611 | $10K | |
| 73610 | <1% | 574 | $10K | |
| 70496 | <1% | 36 | $10K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 465 | $10K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 104 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 411 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,033 | $9K |
| 84466 | <1% | 956 | $9K | |
| 73130 | <1% | 462 | $8K | |
| 81001 | <1% | 11,021 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,791 | $8K |
| J3490 | Unclassified drugs | <1% | 2,586 | $8K |
| 73030 | <1% | 429 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 514 | $7K |
| 83540 | <1% | 993 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,235 | $7K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $7K |
| 64493 | <1% | 17 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,633 | $6K |
| 86803 | <1% | 293 | $6K | |
| 87186 | <1% | 1,309 | $6K | |
| 97032 | <1% | 110 | $6K | |
| 82248 | <1% | 2,906 | $6K | |
| 82043 | <1% | 661 | $6K | |
| 86780 | <1% | 260 | $6K | |
| 73110 | <1% | 377 | $5K | |
| 86140 | <1% | 1,914 | $5K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,703 | $5K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 109 | $5K |
| 84702 | <1% | 390 | $5K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 17 | $5K |
| 80361 | <1% | 518 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 203 | $5K |
| 82140 | <1% | 473 | $5K | |
| 83970 | <1% | 153 | $4K | |
| 80069 | <1% | 223 | $4K | |
| 87147 | <1% | 347 | $4K | |
| 84153 | <1% | 185 | $4K | |
| 84703 | <1% | 2,099 | $4K | |
| 83880 | <1% | 1,520 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,413 | $4K |
| 85018 | <1% | 421 | $4K | |
| 85014 | <1% | 405 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 22 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,370 | $3K |
| 94060 | <1% | 15 | $3K | |
| 97035 | <1% | 50 | $3K | |
| 74018 | <1% | 61 | $3K | |
| 86850 | <1% | 146 | $3K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 52 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 526 | $2K |
| 80346 | <1% | 520 | $2K | |
| 80324 | <1% | 520 | $2K | |
| 80353 | <1% | 520 | $2K | |
| 80358 | <1% | 518 | $2K | |
| 80373 | <1% | 520 | $2K | |
| 80372 | <1% | 518 | $2K | |
| 80355 | <1% | 522 | $2K | |
| 80349 | <1% | 521 | $2K | |
| 0352U | <1% | 138 | $2K | |
| 80356 | <1% | 518 | $2K | |
| 80365 | <1% | 518 | $2K | |
| 80362 | <1% | 519 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 93 | $2K |
| 80354 | <1% | 516 | $2K | |
| 17000 | <1% | 18 | $2K | |
| 80164 | <1% | 233 | $2K | |
| 93971 | <1% | 62 | $2K | |
| 86900 | <1% | 209 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,082 | $2K |
| 85652 | <1% | 680 | $2K | |
| 83690 | <1% | 5,034 | $2K | |
| 72131 | <1% | 13 | $2K | |
| 81003 | <1% | 1,676 | $2K | |
| 82565 | <1% | 203 | $2K | |
| 84100 | <1% | 548 | $2K | |
| 86592 | <1% | 56 | $2K | |
| 82746 | <1% | 304 | $2K | |
| 82077 | <1% | 927 | $1K | |
| 85379 | <1% | 1,438 | $1K | |
| 72110 | <1% | 30 | $1K | |
| 82803 | <1% | 1,162 | $1K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 266 | $1K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 694 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,907 | $1K |
| 82948 | <1% | 1,433 | $1K | |
| 85730 | <1% | 2,264 | $1K | |
| 90715 | <1% | 76 | $1K | |
| 82550 | <1% | 494 | $1K | |
| 87210 | <1% | 89 | $1K | |
| 92523 | <1% | 12 | $1K | |
| 73502 | <1% | 54 | $1K | |
| 84550 | <1% | 213 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 36 | $1K |
| 82553 | <1% | 124 | $974.20 | |
| 96376 | <1% | 1,248 | $849.63 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $833.76 |
| 80076 | <1% | 63 | $815.34 | |
| 87077 | <1% | 183 | $807.05 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 29 | $743.75 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 587 | $721.38 |
| 87040 | <1% | 1,164 | $720.13 | |
| 81015 | <1% | 60 | $719.78 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 80 | $700.84 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 18 | $636.28 |
| 80177 | <1% | 39 | $610.19 | |
| 84156 | <1% | 112 | $602.09 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 441 | $581.41 |
| 80143 | <1% | 599 | $554.78 | |
| 86901 | <1% | 209 | $497.38 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 26 | $488.12 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 254 | $472.89 |
| 87503 | <1% | 60 | $432.16 | |
| 82150 | <1% | 294 | $402.29 | |
| 97116 | <1% | 32 | $398.42 | |
| 82947 | <1% | 147 | $392.16 | |
| 73140 | <1% | 19 | $380.50 | |
| 80074 | <1% | 13 | $359.58 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 782 | $335.30 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 233 | $331.98 |
| 87205 | <1% | 30 | $313.61 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 559 | $304.85 |
| 80179 | <1% | 567 | $299.22 | |
| 81025 | <1% | 668 | $295.44 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,713 | $291.27 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 182 | $267.50 |
| 87070 | <1% | 30 | $255.99 | |
| 97161 | <1% | 30 | $222.31 | |
| 94761 | <1% | 6,231 | $218.64 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 467 | $181.25 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,858 | $171.99 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 44 | $142.08 |
| 36416 | <1% | 259 | $141.04 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 423 | $121.33 |
| 84145 | <1% | 88 | $109.01 | |
| 82962 | <1% | 469 | $101.91 | |
| 84460 | <1% | 16 | $92.75 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 978 | $85.44 |
| 11721 | <1% | 13 | $85.33 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 75 | $73.48 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 13 | $73.26 |
| 36600 | <1% | 19 | $72.50 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 21 | $71.79 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 473 | $59.34 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,195 | $56.19 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 447 | $55.60 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,076 | $51.76 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 326 | $41.59 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 175 | $32.19 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 342 | $30.19 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 730 | $22.19 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 18 | $20.55 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 202 | $17.28 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 88 | $15.47 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,033 | $15.31 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 249 | $14.32 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 246 | $11.70 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 178 | $11.25 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 278 | $8.64 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 163 | $5.07 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 354 | $4.58 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 98 | $4.50 |
| 94760 | <1% | 1,049 | $4.31 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 52 | $3.21 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 131 | $1.44 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 83 | $1.40 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 192 | $0.36 |
| 36000 | 0% | 246 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 1,455 | $0.00 |
| 70498 | 0% | 15 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 30 | $0.00 |
| 64494 | 0% | 16 | $0.00 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 0% | 20 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 382 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 40 | $0.00 |
| 93041 | 0% | 78 | $0.00 | |
| 73590 | 0% | 29 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 17 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARLSON, LISA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Adena Fayette Medical Center | Washington Court House, OH | $1.64M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.